Last reviewed · How we verify
Tranexamic Acid Pill
Tranexamic Acid Pill is a Antifibrinolytic agent Small molecule drug developed by Henry Ford Health System. It is currently FDA-approved for Heavy menstrual bleeding, Prevention of blood loss in surgical procedures, Hemophilia and other bleeding disorders.
Tranexamic acid inhibits the breakdown of blood clots by blocking plasminogen activation, thereby reducing fibrinolysis.
Tranexamic acid is a medication used to treat conditions such as heavy menstrual bleeding, intermenstrual bleeding, menorrhagia, and knee osteoarthritis-related blood loss. It is administered as a pill, often compared to a placebo in clinical trials, and its mechanism of action is related to its ability to inhibit the breakdown of fibrin clots, as indicated by its entry in ChEMBL.
At a glance
| Generic name | Tranexamic Acid Pill |
|---|---|
| Sponsor | Henry Ford Health System |
| Drug class | Antifibrinolytic agent |
| Target | Plasminogen / Plasmin |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Mechanism of action
Tranexamic acid is an antifibrinolytic agent that competitively inhibits the conversion of plasminogen to plasmin, preventing the degradation of fibrin in blood clots. By stabilizing clots and reducing excessive fibrinolysis, it helps control bleeding in conditions characterized by abnormal or excessive fibrin breakdown.
Approved indications
- Heavy menstrual bleeding
- Prevention of blood loss in surgical procedures
- Hemophilia and other bleeding disorders
- Traumatic hemorrhage
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Headache
- Thromboembolic events (rare)
Key clinical trials
- Platelet Transfusions in Hematopoietic Stem Cell Transplantation (The PATH III Trial) (PHASE3)
- Tranexamic Acid to Reduce Contraceptive-related Bleeding Side Effects (PHASE4)
- Extended Postoperative Oral Tranexamic Acid in Knee Replacement (PHASE4)
- Clinical Trial Analyzing the Efficacy of Oral Administration of Tranexamic Acid in Spine Surgery. (PHASE4)
- Nonsurgical Management of Cesarean Scar Niche Related Abnormal Uterine Bleeding (NA)
- Early Administration Of Tranexamic Acid And Acute Blood Loss In Patients With Hip Fractures (PHASE3)
- American Trial Using Tranexamic Acid in Thrombocytopenia (PHASE3)
- Ulipristal Use in Chinese Population (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tranexamic Acid Pill CI brief — competitive landscape report
- Tranexamic Acid Pill updates RSS · CI watch RSS
- Henry Ford Health System portfolio CI
Frequently asked questions about Tranexamic Acid Pill
What is Tranexamic Acid Pill?
How does Tranexamic Acid Pill work?
What is Tranexamic Acid Pill used for?
Who makes Tranexamic Acid Pill?
What drug class is Tranexamic Acid Pill in?
What development phase is Tranexamic Acid Pill in?
What are the side effects of Tranexamic Acid Pill?
What does Tranexamic Acid Pill target?
Related
- Drug class: All Antifibrinolytic agent drugs
- Target: All drugs targeting Plasminogen / Plasmin
- Manufacturer: Henry Ford Health System — full pipeline
- Therapeutic area: All drugs in Hematology
- Indication: Drugs for Heavy menstrual bleeding
- Indication: Drugs for Prevention of blood loss in surgical procedures
- Indication: Drugs for Hemophilia and other bleeding disorders
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing